Accelerating Medicines Partnership Announces Awards to Advance Research in Type 2 Diabetes
The Foundation for the National Institutes of Health (FNIH) will award more than $3.5 million to further the study of Type 2 Diabetes (T2D) as part of an unprecedented collaboration to develop new ways to diagnose and treat several pressing diseases. The awards are the first funds to be released from the FNIH for the T2D initiative, which is a component of the Accelerating Medicines Partnership (AMP), a joint venture among the National Institutes of Health (NIH), the Food and Drug Administration (FDA), 10 biopharmaceutical companies and several non-profits to identify and validate promising biological targets of disease.
Read more >>
Donate and Support Today
Take Action to Support Life-Saving Medical Research
Every dollar counts! Your gift to the FNIH makes our efforts possible. With your help—and in partnership with NIH—the Foundation is advancing biomedical research and training.
Donate with Confidence
For 10 years, Charity Navigator has rated FNIH as an organization that exceeds industry standards.
News and Highlights
The FNIH Award Ceremony and presentation of the 2015 Lurie Prize in Biomedical Sciences will be held May 20, in Washington, D.C. Individual and table tickets are now available, as are sponsorship opportunities. Click here to learn more >>
FNIH has selected Karl Deisseroth, M.D., Ph.D., as the 2015 winner of the Lurie Prize in Biomedical Sciences for the development of optogenetics and CLARITY as tools to study the functions of cells, especially neurons. More >>
The FNIH is pleased to accept applications for Heart Truth® Community Action Program grants now through March 25. Grants enable community organizations to equip women to know and address their risk for heart disease, the leading cause of death for women in the U.S.
A new study demonstrates the significant impact of FNIH’s research. The Innovative Medicines Initiative (IMI), a European public-private program working to speed the development of better and safer medicines for patients, released a study commissioned from the independent firm Thomson Reuters that measured how often publications arising from research projects of major biomedical research organizations, such as IMI and FNIH, were cited by others. The five organizations the study compared had a “citation impact” of about twice the world average, “indicating highly-cited internationally significant research.” Among them, the FNIH had the highest percentage—28.8 percent—of highly cited papers. Read the study here >>